Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera’s mission is to discover, develop and commercialize innovative therapeutics targeting the ubiquitin system and other novel pathways to extend the lives and improve the quality of life of patients suffering from cancer and other serious diseases.

Kymera’s vision is to be a world-leading biopharmaceutical company, providing innovative solutions and cures for serious diseases through the use of its proprietary precision medicine technology platform and a powerful pipeline of pioneering compounds.

Kymera was recognized by FierceBiotech as one of The 10 Most Impressive Biotech Startups of 2019 and was featured in The Wall Street Journal Innovation Awards in 2020.